Literature DB >> 7904107

Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks.

J Faergemann1, H Zehender, J Denouël, L Millerioux.   

Abstract

The distribution of terbinafine in stratum corneum dermis-epidermis (without stratum corneum), sebum, hair, nails and plasma was studied in human male volunteers during and after 250 mg orally once daily for 28 days. The highest concentration was seen in sebum, 56.07 micrograms/g, after 14 days of therapy. The concentration was still 1.0 microgram/g 44 days after stop of medication. In stratum corneum the highest concentration, 14.4 micrograms/g, was seen 1 day after the last day of therapy, and it was 2.1 micrograms/g 44 days after stop of medication. The concentrations in hair and nails were lower with a maximum of 2.36 and 0.39 micrograms/g respectively, 1 day after stop of therapy, and still 0.21 microgram/g in hair and 0.09 microgram/g in nails 55 days after the last day of medication. With the exception of nails, all other tissue levels were at all times above the plasma concentrations. For nails, tissue levels exceeded that of plasma as early as 1 day after stop of medication, and this difference continued to increase until the last day of tissue sampling, 55 days after the last tablet. These results indicate that terbinafine is delivered to the stratum corneum through sebum and to a minor extent by direct diffusion through dermis-epidermis. Probably short-term therapy with terbinafine may be effective in the treatment of several dermatomycoses, due to the strong binding of terbinafine to stratum corneum for a long time after stop of medication.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7904107     DOI: 10.2340/000155557300304

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  25 in total

Review 1.  Drugs in nails: physiology, pharmacokinetics and forensic toxicology.

Authors:  A Palmeri; S Pichini; R Pacifici; P Zuccaro; A Lopez
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Antifungal agents for common paediatric infections.

Authors: 
Journal:  Paediatr Child Health       Date:  2007-12       Impact factor: 2.253

4.  Antifungal agents for common paediatric infections.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

Review 5.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

6.  An ex vivo toe model used to assess applicators for the iontophoretic ungual delivery of terbinafine.

Authors:  Anroop B Nair; Hyun D Kim; Shawn P Davis; Robert Etheredge; Michael Barsness; Phillip M Friden; S Narasimha Murthy
Journal:  Pharm Res       Date:  2009-07-07       Impact factor: 4.200

7.  Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.

Authors:  Michael J Dolton; Vidya Perera; Lisa G Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

8.  Antifungal agents for common paediatric infections.

Authors: 
Journal:  Paediatr Child Health       Date:  2000-11       Impact factor: 2.253

9.  Correlation of In Vitro Susceptibility Based on MICs and Squalene Epoxidase Mutations with Clinical Response to Terbinafine in Patients with Tinea Corporis/Cruris.

Authors:  Ananta Khurana; Aradhana Masih; Anuradha Chowdhary; Kabir Sardana; Sagar Borker; Aastha Gupta; R K Gautam; P K Sharma; Dhruv Jain
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 10.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.